Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 81c, provides guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $230.25 +1.92%
EPS Growth %: +174.9%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +174.9%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $6.60, $0.81 better than the analyst estimate of $5.79. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2025 EPS of $22.50-$24.00, versus the consensus of $22.03.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
- Cerebras Q1 EPS miss sends shares down 9% after-hours
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
